Surmodics
Market Cap
US$629.7m
Last Updated
2019/09/17 23:42 UTC
Data Sources
Company Financials +
Executive Summary
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally.
Snowflake
Fundamentals
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Surmodics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
5.4%
NasdaqGS:SRDX
1.5%
US Medical Equipment
0.8%
US Market
1 Year Return
-40.9%
NasdaqGS:SRDX
9.7%
US Medical Equipment
1.9%
US Market
SRDX underperformed the Medical Equipment industry which returned 9.6% over the past year.
SRDX underperformed the Market in United States of America which returned 2.1% over the past year.
Share holder returns
| SRDX | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.4% | 1.5% | 0.8% |
| 30 Day | 4.8% | 0.7% | 3.4% |
| 90 Day | 7.6% | 2.4% | 2.1% |
| 1 Year | -40.9%-40.9% | 10.6%9.7% | 4.2%1.9% |
| 3 Year | 63.7%63.7% | 70.2%65.0% | 46.7%37.2% |
| 5 Year | 155.1%155.1% | 136.0%109.1% | 62.3%44.5% |
Price Volatility Vs. Market
How volatile is Surmodics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Should We Be Cautious About Surmodics, Inc.'s (NASDAQ:SRDX) ROE Of 1.9%?4 weeks ago | Simply Wall St
Is There An Opportunity With Surmodics, Inc.'s (NASDAQ:SRDX) 42% Undervaluation?1 month ago | Simply Wall St
Surmodics, Inc.’s (NASDAQ:SRDX) Investment Returns Are Lagging Its IndustryValuation
Is Surmodics undervalued based on future cash flows and its price relative to the stock market?
25%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Surmodics's share price is below the future cash flow value, and at a moderate discount (> 20%).
Surmodics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
Price Based on Earnings
Surmodics is overvalued based on earnings compared to the US Medical Equipment industry average.
Surmodics is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Surmodics is poor value based on expected growth next year.
Price Based on Value of Assets
Surmodics is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Surmodics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?
20.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Surmodics's revenue is expected to grow by 11.2% yearly, however this is not considered high growth (20% yearly).
Surmodics's earnings are expected to grow significantly at over 20% yearly.
Surmodics's revenue growth is expected to exceed the United States of America market average.
Surmodics's earnings growth is expected to exceed the United States of America market average.
Surmodics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Surmodics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Surmodics performed over the past 5 years?
-47.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Surmodics's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
Surmodics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
Surmodics has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.
Return on Equity
Surmodics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Surmodics used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.
Return on Capital Employed
Surmodics's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Surmodics's financial position?
Financial Position Analysis
Surmodics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Surmodics's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Surmodics has no debt.
Surmodics has not taken on any debt in the past 5 years.
Surmodics has no debt, it does not need to be covered by operating cash flow.
Surmodics has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
High level of physical assets or inventory.
Surmodics has no debt, it does not need to be covered by short term assets.
Next Steps
Dividend
What is Surmodics's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Surmodics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Surmodics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Surmodics has not reported any payouts.
Unable to verify if Surmodics's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Surmodics has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Surmodics's salary, the management and board of directors tenure and is there insider trading?
3.8yrs
Average management tenure
CEO
Gary Maharaj (56yo)
8.8yrs
Tenure
US$2,402,237
Compensation
Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006 ...
CEO Compensation Analysis
Gary's remuneration is about average for companies of similar size in United States of America.
Gary's compensation has increased in line with Surmodics recently becoming profitable.
Management Age and Tenure
3.8yrs
Average Tenure
53yo
Average Age
The tenure for the Surmodics management team is about average.
Board Age and Tenure
5.6yrs
Average Tenure
63yo
Average Age
The tenure for the Surmodics board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 2,569 |
| Max Price | US$57.38 |
Ownership Breakdown
Management Team
Charlie Olson (55yo)
Senior Vice President of Commercial & Business Development - Medical Devices
- Tenure: 14.9yrs
- Compensation: US$903.23k
Gregg Sutton (59yo)
Vice President of Research & Development - Medical Devices
- Tenure: 3.7yrs
- Compensation: US$864.91k
Gary Maharaj (56yo)
CEO, President & Director
- Tenure: 8.8yrs
- Compensation: US$2.40m
Bryan Phillips (48yo)
Senior VP of Legal
- Tenure: 11yrs
- Compensation: US$962.94k
Joe Stich (54yo)
VP & GM of In-Vitro Diagnostics
- Tenure: 8.1yrs
- Compensation: US$696.13k
Tim Arens (52yo)
Chief Financial Officer
- Tenure: 1.3yrs
- Compensation: US$798.63k
Tom Greaney (53yo)
Chief Operating Officer of Medical Devices
- Tenure: 3.8yrs
- Compensation: US$971.90k
John Manders (38yo)
Corporate Controller & Principal Accounting Officer
- Tenure: 1.3yrs
Teryl L. Sides (50yo)
Senior VP & Chief Marketing Officer
- Tenure: 0.8yrs
Board Members
Shawn McCormick (55yo)
Independent Director
- Tenure: 3.8yrs
- Compensation: US$145.50k
Ron Kalich (72yo)
Independent Director
- Tenure: 5.6yrs
- Compensation: US$156.00k
David Dantzker (76yo)
Independent Director
- Tenure: 8.7yrs
- Compensation: US$151.00k
Sue Knight (65yo)
Chairman of The Board
- Tenure: 4.7yrs
- Compensation: US$219.00k
José Bedoya (63yo)
Independent Director
- Tenure: 17.7yrs
- Compensation: US$148.00k
Gary Maharaj (56yo)
CEO, President & Director
- Tenure: 8.8yrs
- Compensation: US$2.40m
Lisa Heine (55yo)
Director
- Tenure: 2.4yrs
- Compensation: US$144.00k
Company Information
Surmodics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Surmodics, Inc.
- Ticker: SRDX
- Exchange: NasdaqGS
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$629.741m
- Shares outstanding: 13.49m
- Website: https://www.surmodics.com
Number of Employees
Location
- Surmodics, Inc.
- 9924 West 74th Street
- Eden Prairie
- Minnesota
- 55344
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SRDX | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Mar 1998 |
| SU6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Mar 1998 |
Biography
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates thro ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/17 23:42 |
| End of Day Share Price | 2019/09/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.